老年2型糖尿病共病患者多重用药的临床观察
广州中医药大学顺德医院附属勒流医院(佛山市顺德区勒流医院)
目的 观察老年2型糖尿病(T2DM)共病患者的多重用药情况。方法 选取2023年1月至2024年3月我院收治的198例老年T2DM共病患者作为研究对象,收集患者一般资料、诊断及用药信息,分析住院期间及出院后的多重用药(≥5种)与不当用药情况。结果 198例患者年龄为60~91岁,平均(73.45±7.54)岁;平均诊断结果数(7.83±1.53)个。降糖药物中,双胍类(67.17%)、α-糖苷酶抑制剂(46.46%)、钠-葡萄糖协同转运蛋白-2抑制剂(37.37%)和二肽基肽酶-4抑制剂(38.38%)使用率较高;降压药物以血管紧张素Ⅱ受体拮抗剂(37.37%)、β-受体阻滞剂(26.77%)和钙通道阻滞剂(25.25%)为主。依据《中国老年人潜在不适当用药判断标准(2017版)》评估,28份病历(14.14%)存在41例次不当用药。结论 老年T2DM共病患者中多重用药现象普遍,且存在不当用药风险,临床需加强用药审查与指导。
Objective To observe the polypharmacy situation in elderly patients with comorbidities of type 2 diabetes mellitus(T2DM).Methods A total of 198 elderly patients with comorbidities of T2DM admitted to our hospital from January 2023 to March 2024 were selected as the research subjects.General data,diagnosis and medication information were collected,and the situations of multiple medications(≥5 kinds) and improper medication during hospitalization and after discharge were analyzed.Results The ages of 198 patients ranged from 60 to 91 years old(73.45±7.54 years old).The average number of diagnostic results was(7.83±1.53).Among hypoglycemic drugs,biguanides(67.17%),a-glycosidase inhibitors(46.46%),sodium-glucose cotransporter-2 inhibitors(37.37%),and dipeptidyl peptidase-4 inhibitors(38.38%) have relatively high usage rates.Antihypertensive drugs are mainly angiotensin Ⅱ receptor antagonists(37.37%),beta-blockers(26.77%),and calcium channel blockers(25.25%).According to the "Criteria for Judging Potentially Inappropriate Medication Use in Chinese Elderly People(2017 Edition)",41 cases of improper medication use were found in 28 medical records(14.14%).Conclusion Among elderly patients with comorbidities of T2DM,the phenomenon of polypharmacy is widespread,and there is a risk of improper medication.Clinically,it is necessary to strengthen the review and guidance of medication.
引用本文
按标准格式复制,或导出到文献管理软件参考文献
共 14 条- [1]Sanz-Cánovas J,López-Sampalo A,Cobos-Palacios L,et al.Management of Type 2 Diabetes Mellitus in Elderly Patients with Frailty and/or Sarcopenia[J].Int J Environ Res Public Health,2022,19(14):8677.
- [2]申学谦.社区卫生服务中心老年糖尿病患者处方多重用药情况分析[J].中国医药,2021,16(1):80-84.
- [3]曾森祥,杨锐,邓勋,等.老年2型糖尿病合并动脉粥样硬化性心血管疾病多重用药管理规范[J].中国全科医学,2024,27(5):597-603.
- [4]曾艳,张茹.对老年2型糖尿病住院患者多重用药相互作用的分析及干预研究[J].实用药物与临床,2019,22(5):535-540.
- [5]舒冰,方玉婷,李民,等.老年多重用药患者潜在不适当用药情况及其影响因素研究[J].中国全科医学,2021,24(17):2134-2139.
- [6]中国老年保健医学研究会老年合理用药分会,等.中国老年人潜在不适当用药判断标准(2017版)[J].中国全科医学,2018,21(29):3463-3470.
- [7]Boersma P,Black LI,Ward BW.Prevalence of Multiple Chronic Conditions Among US Adults,2018[J].Prev Chronic Dis,2020,17:E106.
- [8]田蓉,傅桂芬,李丽蓉,等.老年T2DM合并高血压患者发生糖尿病肾病的影响因素[J].心血管康复医学杂志,2023,32(1):4-8.
- [9]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):315-409.
- [10]Giaccari A,Giorda CB,Riccardi G,et al.Comment on:Inzucchi et al.Management of hyperglycemia in type 2 diabetes:a patient-centered approach.Position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J].Diabetes Care,2012,35:1364-1379.
- [11]Sattar N,Lee MMY,Kristensen SL,et al.Cardiovascular,mortality,and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes:a systematic review and meta-analysis of randomised trials[J].Lancet Diabetes Endocrinol,2021,9(10):653-662.
- [12]蔡昳,吴建博,刘璐瑶,等.老年2型糖尿病共病患者糖化血红蛋白达标的影响因素[J].中华老年多器官疾病杂志,2022,21(1):1-5.
- [13]李艳,李佳颖,严小芳,等.国产吲达帕胺应用于高血压的安全性及其影响因素[J].临床药物治疗杂志,2022,20(12):60-66.
- [14]栗芳,陈张勇,吐达洪,等.基于我国标准社区老年患者潜在不适当用药分析[J].临床药物治疗杂志,2022,20(6):58-62.
| 文章编号 | 2026-01-017(期号内编号) |
|---|---|
| 栏目 | 临床药物与手术治疗 |
| 作者 | 陈协生;伍翠璧;杨春龙;杨树洧;郭西宁;梁永洪 |
| 作者单位 | 广州中医药大学顺德医院附属勒流医院(佛山市顺德区勒流医院) |
| 基金项目 | 2023年佛山市自筹经费类科技计划项目(222000104031)资助:《领航计划——佛山市顺德区医学骨干人才培养项目》 |
| 中图分类号 | R587.1 |
| 卷期页码 | 2026, 2(01): 125-128 |
| 发布时间 | 2026-01-15 |
| 出版时间 | 2026-01-15 |
| 引用信息 | [1]陈协生,伍翠璧,杨春龙,等.老年2型糖尿病共病患者多重用药的临床观察[J].疾病预防与控制,2026,2(01):125-128. |
| 全文地址 | 在知网查看该文(kns.cnki.net) |
| 数据抓取时间 | 2026-09-22T12:24:48 |